Baird analyst Brian Skorney reiterated an Outperform rating and $64.00 price target on Aimmune Therapeutics (NASDAQ: AIMT) saying they are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC CapitalMarch 26, 2019 6:27 AM Aimmune Therapeutics (AIMT) Says European Phase 3 Trial of its AR101 Meets Primary EndpointMarch 25, 2019 8:01 AM European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary EndpointMarch 25, 2019 8:00 AM